312 related articles for article (PubMed ID: 16629057)
1. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.
Wilton SD; Fletcher S
Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057
[TBL] [Abstract][Full Text] [Related]
2. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
3. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
[TBL] [Abstract][Full Text] [Related]
4. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
5. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
Niks EH; Aartsma-Rus A
Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
[TBL] [Abstract][Full Text] [Related]
6. Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
Yokota T; Duddy W; Echigoya Y; Kolski H
Expert Opin Biol Ther; 2012 Sep; 12(9):1141-52. PubMed ID: 22650324
[TBL] [Abstract][Full Text] [Related]
7. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
Wilton SD; Fletcher S
Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827
[TBL] [Abstract][Full Text] [Related]
8. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
9. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
10. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
11. Splicing intervention for Duchenne muscular dystrophy.
McClorey G; Fletcher S; Wilton S
Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
[TBL] [Abstract][Full Text] [Related]
12. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
13. Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.
Yokota T; Pistilli E; Duddy W; Nagaraju K
Expert Opin Biol Ther; 2007 Jun; 7(6):831-42. PubMed ID: 17555369
[TBL] [Abstract][Full Text] [Related]
14. Multiple exon skipping strategies to by-pass dystrophin mutations.
Adkin CF; Meloni PL; Fletcher S; Adams AM; Muntoni F; Wong B; Wilton SD
Neuromuscul Disord; 2012 Apr; 22(4):297-305. PubMed ID: 22182525
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
Popplewell LJ; Graham IR; Malerba A; Dickson G
Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
[TBL] [Abstract][Full Text] [Related]
16. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.
Mann CJ; Honeyman K; Cheng AJ; Ly T; Lloyd F; Fletcher S; Morgan JE; Partridge TA; Wilton SD
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):42-7. PubMed ID: 11120883
[TBL] [Abstract][Full Text] [Related]
17. Overview on DMD exon skipping.
Aartsma-Rus A
Methods Mol Biol; 2012; 867():97-116. PubMed ID: 22454057
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.
Madden HR; Fletcher S; Davis MR; Wilton SD
Hum Mutat; 2009 Jan; 30(1):22-8. PubMed ID: 18570328
[TBL] [Abstract][Full Text] [Related]
19. Exon skipping therapy for Duchenne muscular dystrophy.
Kole R; Krieg AM
Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
[TBL] [Abstract][Full Text] [Related]
20. Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping.
Mitrpant C; Fletcher S; Wilton SD
Curr Mol Pharmacol; 2009 Jan; 2(1):110-21. PubMed ID: 20021451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
